A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
Journal of Gastroenterology and Hepatology · 2026-04 · 41 (4) · 1311-1322
DOI: 10.1111/jgh.70294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 16.02.2026. Verfasst von Ziqi V Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Liver Enzymes in Metabolism and Inflammation, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales,…. Hauptthemen laut MEDLINE: Gelatinases, Membrane Proteins, Liver Cirrhosis, Serine Endopeptidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Rebecca L. Cooper Medical Research Foundation, Centenary Institute Foundation.
Abstract (Originalsprache)
Background
Noninvasive fibrosis testing is crucial for metabolic dysfunction–associated steatotic liver disease (MASLD) management. This study evaluated a marker of activated mesenchymal fibrogenic cells, circulating fibroblast activation protein (cFAP), in a novel diagnostic algorithm, FAP Index, for patients with MASLD.
Methods
Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training ( n = 160) and external validation cohorts ( n = 332), with prevalence of histologic advanced fibrosis (F3–F4) of 20% and 11%, respectively. cFAP was measured using our rapid single‐step FAP‐specific microplate enzyme assay. A predictive model, FAP Index, containing age, type 2 diabetes, alanine transaminase, and ordinal cFAP was developed using logistic regression; then, its diagnostic accuracy was evaluated.
Results
FAP Index AUROC for advanced fibrosis was 0.875 (95% CI: 0.813–0.938) in the training cohort and 0.841 (95% CI: 0.776–0.906) in the validation cohort. Low cutoff 0.157 (sensitivity 84.3%, negative predictive value 95%) and high cutoff 0.695 (specificity 99.2%, positive predictive value 92.9%) values excluded and predicted advanced fibrosis, respectively. FAP Index following FIB‐4 reduced the frequency of indeterminate results by more than one‐third compared to FIB‐4 alone. FAP Index following NFS (NAFLD Fibrosis Score) reduced the frequency of indeterminate results by ~70% compared to NFS alone.
Conclusion
Without a need for elastography, applying FAP Index following FIB‐4 or NFS can facilitate accurate risk stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB‐4 or NFS alone, without compromising negative predictive value. Thus, FAP Index is a novel, fibrogenesis‐relevant, rapid, robust diagnostic tool suited to increasing the efficiency of liver fibrosis triage in primary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Enzymes in Metabolism and Inflammation, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Developmental, Molecular and Chemical Biology, Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts, USA.
- Obesity Surgery WA, Booragoon, Western Australia, Australia.
- Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Wilrijk, Belgium.
- Nordic Bioscience A/S, Herlev, Denmark.
- Department of Surgery, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Ziqi V Wang, Badwi B Boumelhem, William W Bachovchin, Jack Hung-Sen Lai, Sarah E Poplawski, Pieter Van Der Veken, Diana Julie Leeming, Geraldine Ooi, Jacob George, Mohammed Eslam, Leon A Adams, Hui Emma Zhang, Geoffrey W McCaughan, Avik Majumdar, Mark D Gorrell
Förderung
- National Health and Medical Research Council
- Rebecca L. Cooper Medical Research Foundation
- Centenary Institute Foundation
- Gilead Fellowship
- Robert W. Storr Bequest to the Sydney Medical Foundation
- Hollywood Private Hospital Research Foundation
- Sir Charles Gairdner Osborne Parke Health Care Group
Zitieren
APA
Wang, Z. V., Boumelhem, B. B., Pennell, T., Bachovchin, W. W., Lai, J. H., Poplawski, S. E., Chandraratna, H., Van Der Veken, P., Brewer, K., Leeming, D. J., Ooi, G., George, J., Eslam, M., Adams, L. A., Zhang, H. E., McCaughan, G. W., Majumdar, A., & Gorrell, M. D. (2026). A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Gastroenterology and Hepatology, 41(4), 1311-1322. https://doi.org/10.1111/jgh.70294
Vancouver
Wang ZV, Boumelhem BB, Pennell T, Bachovchin WW, Lai JH, Poplawski SE, et al. A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Gastroenterology and Hepatology. 2026;41(4):1311-1322. doi:10.1111/jgh.70294
BibTeX
@article{Wang2026,
author = {Wang, Ziqi V and Boumelhem, Badwi B and Pennell, Torsten and Bachovchin, William W and Lai, Jack Hung-Sen and Poplawski, Sarah E and Chandraratna, Harsha and Van Der Veken, Pieter and Brewer, Kate and Leeming, Diana Julie and Ooi, Geraldine and George, Jacob and Eslam, Mohammed and Adams, Leon A and Zhang, Hui Emma and McCaughan, Geoffrey W and Majumdar, Avik and Gorrell, Mark D},
title = {A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {4},
pages = {1311--1322},
doi = {10.1111/jgh.70294}
}
EUVIMED